207 Results

People

  1. Giralt
    Giralt
  2. Landau
    Landau
  3. Lesokhin
    Lesokhin
  4. Hassoun
    Hassoun
  5. Chung
    Chung
  6. Shah
    Shah
  7. Mailankody
    Mailankody
  8. Korde
    Korde
  9. Scordo
    Scordo
  10. Devlin
    Devlin

Groups

  1. Bone Marrow Transplant (207)
  2. Center for Hematologic Malignancies (207)
  3. Department of Medicine (207)
  4. Hematologic Malignancies Research (207)
  5. Hematologic Malignancies, Division of (207)
  6. Survivorship Research (188)
  7. Myeloma (162)
  8. Epidemiology and Biostatistics (145)
  9. Biostatistics Service (138)
  10. CTCR Scholars (122)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Sergio Giralt"
Formats
  1. Meeting Abstract (148)
  2. Journal Article (55)
  3. Research Letter (3)
  4. Correspondence (1)
Groups
  1. Bone Marrow Transplant (207)
  2. Center for Hematologic Malignancies (207)
  3. Department of Medicine (207)
  4. Hematologic Malignancies Research (207)
  5. Hematologic Malignancies, Division of (207)
  6. Survivorship Research (188)

More Groups

People
  1. Sergio Giralt (207)
  2. Alexander Lesokhin (144)
  3. Heather Landau (144)
  4. Hani Hassoun (140)
  5. David Chung (139)
  6. Gunjan Shah (121)

More People

Years
  1. 2023 (35)
  2. 2022 (25)
  3. 2021 (19)
  4. 2020 (22)
  5. 2019 (18)
  6. 2018 (14)

More Years

Publications
  1. Blood (90)
  2. Biology of Blood and Marrow Transplantation (30)
  3. Clinical Lymphoma, Myeloma and Leukemia (29)
  4. Leukemia and Lymphoma (9)
  5. Bone Marrow Transplantation (8)
  6. Journal of Clinical Oncology (7)

More Publications

Publishers
  1. American Society of Hematology (95)
  2. Elsevier Inc. (62)
  3. Nature Publishing Group (16)
  4. Taylor & Francis Group (9)
  5. American Society of Clinical Oncology (7)
  6. American Association for Cancer Research (4)

More Publishers

Results (207)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long term follow-up after treatment with allogeneic off-the-shelf CAR T cell therapy for relapsed or refractory B-cell malignancies
    Meeting Abstract

    Shahid, S.; Flynn, G. C.; Mauguen, A.; Bieler, J.; Prockop, S. E.; Scaradavou, A.; Boelens, J. J.; Sauter, C. S.; Perales, M. A.; Giralt, S. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) and daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • T-cell exhaustion signature predicts early relapse after autologous stem cell transplant for multiple myeloma: BMT CTN 0702 secondary immune analysis
    Meeting Abstract

    Mehanna, N.; Derkach, A.; Gasmi, B.; Anagnostou, T.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Maclachlan, K. H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab-based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K. H.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Serrano, E.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Ziccheddu, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • The complex structural variant chromothripsis can be defined on targeted sequencing panels, allowing direct clinical translation in order to improve multiple myeloma prognostication
    Meeting Abstract

    Maclachlan, K. H.; Ziccheddu, B.; Tan, C.; Shekarkhand, T.; Rueda, C.; Serrano, E.; Diamond, B.; Hassoun, H.; Mailankody, S.; Shah, U. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Identifying causes of unscheduled healthcare interactions and changes to patient disposition in individuals receiving outpatient commercial bispecific antibody therapy in relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Howard, A. J.; Shekarkhand, T.; Hamadeh, I. S.; Wang, A.; Patel, D.; Tan, C.; Hultcrantz, M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves quality of life, metabolic, microbiome and immune profile in MGUS/SMM as well as progression trajectory in a subset - the Nutrivention trial
    Meeting Abstract

    Shah, U. A.; Castro, F.; Derkach, A.; Fei, T.; Hosszu, K. K.; McAvoy, D.; DeWolf, S.; Cross, J.; Gradissimo, A.; Nwankwo, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Carfilzomib,lenalidomide and dexamethasone (KRd) as induction therapy in high-risk newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Korde, N.; Derkach, A.; Hultcrantz, M.; Maclachlan, K. H.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Meeting Abstract

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating the effect of evolving changes in serum biomarkers on the risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K. H.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Blood (2023)

    Fulltext@MSK | Save